{"doi":"10.1111/head.14474","title":"Impact of preventive pill‐based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention ( <scp>CHAMP</scp> ) trial and a comparison of self‐report to nosology‐derived assessments","abstract":"OBJECTIVE: To examine group differences in self-reported migraine days among youth who completed the Childhood and Adolescent Migraine Prevention (CHAMP) trial prior to its closure and explore the relationship between self-reported and \"nosology-derived\" (i.e., International Classification of Headache Disorders, 3rd edition [ICHD-3]) migraine days. BACKGROUND: The CHAMP trial compared amitriptyline and topiramate to placebo for migraine prevention in youth and proposed to analyze change in migraine days as a secondary outcome. There is considerable variability in the field regarding what constitutes a \"migraine day,\" how this is determined and reported in trials, and how consistent these measures are with diagnostic nosology. METHODS: CHAMP trial completers (N = 175) were randomized to receive amitriptyline (n = 77), topiramate (n = 63), or placebo (n = 35). Participants maintained daily headache diaries where they reported each day with headache and if they considered that headache to be a migraine. For each headache day, participants completed a symptom record and reported about symptoms such as pain location(s) and presence of nausea/vomiting or photophobia and phonophobia. We examined group differences in self-reported migraine days at trial completion (summed from trial weeks 20-24) compared to baseline. We also used an algorithm to determine whether participants' symptom reports met ICHD-3 criteria for migraine without aura, and examined the association between self-reported and \"nosology-derived\" migraine days. RESULTS: Results showed no significant differences between groups in self-reported migraine days over the course of the trial. Self-reported and \"nosology-derived\" migraine days during the baseline and treatment phases were strongly associated (r's = 0.73 and 0.83, respectively; p's < 0.001). CONCLUSION: Regardless of treatment, CHAMP trial completers showed clinically important reductions in self-reported migraine days over the course of the trial (about 3.8 days less). The strong association between self-reported and \"nosology-derived\" migraine days suggests youth with migraine can recognize a day with migraine and reliably report their headache features and symptoms. Greater rigor and transparency in the calculation and reporting of migraine days in trials is needed.","journal":"Headache The Journal of Head and Face Pain","year":2023,"id":372167,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9408,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":334487,"name":"James Peugh","orcid":"0000-0002-1134-5667","position":1,"is_corresponding":false},{"id":275409,"name":"Christopher S. Coffey","orcid":"0000-0002-8130-5484","position":2,"is_corresponding":false},{"id":415134,"name":"Leigh A. Chamberlin","orcid":null,"position":3,"is_corresponding":false},{"id":501090,"name":"Dixie Ecklund","orcid":"0000-0001-6086-962X","position":4,"is_corresponding":false},{"id":502027,"name":"Elizabeth Klingner","orcid":null,"position":5,"is_corresponding":false},{"id":502029,"name":"Jon Yankey","orcid":null,"position":6,"is_corresponding":false},{"id":783352,"name":"Leslie Korbee","orcid":null,"position":7,"is_corresponding":false},{"id":783354,"name":"Marielle A. Kabbouche","orcid":null,"position":8,"is_corresponding":false},{"id":782885,"name":"Joanne Kacperski","orcid":"0000-0003-0226-7668","position":9,"is_corresponding":false},{"id":783353,"name":"Linda Porter","orcid":null,"position":10,"is_corresponding":false},{"id":782884,"name":"Brooke L. Reidy","orcid":"0000-0002-3542-8037","position":11,"is_corresponding":false},{"id":414437,"name":"Andrew D. Hershey","orcid":"0000-0002-1598-7536","position":12,"is_corresponding":false},{"id":414438,"name":"Scott W. Powers","orcid":"0000-0002-5348-9650","position":13,"is_corresponding":false},{"id":728308,"name":"Robert C. Gibler","orcid":"0000-0002-1532-7044","position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":null,"created_at":"2026-07-19T01:15:54.000926Z","pmid":"36757131","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}